Omeros Co. (NASDAQ:OMER) Shares Purchased by Nomura Holdings Inc.

Nomura Holdings Inc. boosted its stake in Omeros Co. (NASDAQ:OMER - Free Report) by 136.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 747,281 shares of the biopharmaceutical company's stock after buying an additional 430,932 shares during the period. Nomura Holdings Inc. owned approximately 1.29% of Omeros worth $7,383,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Truvestments Capital LLC increased its stake in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,669 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new stake in Omeros in the fourth quarter worth approximately $46,000. Picton Mahoney Asset Management grew its holdings in shares of Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock valued at $50,000 after buying an additional 4,404 shares during the last quarter. Finally, US Bancorp DE purchased a new position in Omeros during the fourth quarter worth about $81,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Stock Performance

Shares of OMER traded down $0.14 during midday trading on Tuesday, hitting $3.18. 515,897 shares of the company traded hands, compared to its average volume of 654,296. Omeros Co. has a 52 week low of $2.97 and a 52 week high of $13.60. The firm has a 50 day moving average of $6.97 and a 200-day moving average of $8.16. The stock has a market cap of $185.41 million, a price-to-earnings ratio of -1.40 and a beta of 2.42.

Omeros (NASDAQ:OMER - Get Free Report) last issued its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05). Sell-side analysts predict that Omeros Co. will post -3.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OMER has been the subject of a number of research analyst reports. D. Boral Capital restated a "buy" rating and set a $36.00 price objective on shares of Omeros in a report on Tuesday, May 13th. StockNews.com upgraded shares of Omeros from a "sell" rating to a "hold" rating in a research report on Monday. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a report on Friday. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.